|
1.
|
|
13 p, 828.8 KB |
Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions
/
Villatoro, Sergi (Grup Quirónsalud (Barcelona, Catalunya)) ;
Mayo-de-las-Casas, Clara (Grup Quirónsalud (Barcelona, Catalunya)) ;
Jordana-Ariza, Núria (Grup Quirónsalud (Barcelona, Catalunya)) ;
Viteri-Ramírez, Santiago (Grup Quirónsalud (Barcelona, Catalunya)) ;
Garzón-Ibañez, Mónica (Grup Quirónsalud (Barcelona, Catalunya)) ;
Moya-Horno, Irene (Hospital General de Catalunya) ;
García-Peláez, Beatrtiz (Grup Quirónsalud (Barcelona, Catalunya)) ;
González-Cao, María (Grup Quirónsalud (Barcelona, Catalunya)) ;
Malapelle, Umberto (University of Naples Federico II) ;
Balada-Bel, Ariadna (Grup Quirónsalud (Barcelona, Catalunya)) ;
Martínez-Bueno, Alejandro (Grup Quirónsalud (Barcelona, Catalunya)) ;
Campos, Raquel (Grup Quirónsalud (Barcelona, Catalunya)) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Blanco, Remei (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Blasco, Ana (Hospital General Universitari de València) ;
Catalán, María J. (Grup Quirónsalud (Barcelona, Catalunya)) ;
González, Xavier (Hospital General de Catalunya) ;
Troncone, Giancarlo (University of Naples Federico II) ;
Karachaliou, Niki (Hospital del Sagrat Cor (Barcelona, Catalunya)) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Molina-Vila, Miguel Ángel (Grup Quirónsalud (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
Many advanced cases of cancer show central nervous system, pleural, or peritoneal involvement. In this study, we prospectively analyzed if cerebrospinal fluid (CSF), pleural effusion (PE), and/or ascites (ASC) can be used to detect driver mutations and guide treatment decisions. [...]
2019 -  10.1002/1878-0261.12574
Molecular Oncology, Vol. 13 Núm. 12 (january 2019) , p. 2633-2645
|
|
|
2.
|
|
28 p, 884.5 KB |
Cabozantinib for the treatment of solid tumors : a systematic review
/
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Porta, Camillo (Interdisciplinary Department of Medicine. University of Bari "Aldo Moro) ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Apolo, Andrea B. (Center for Cancer Research. National Cancer Institute. National Institutes of Health) ;
Viteri, Santiago (UOMI Cancer Center. Clínica Mi Tres Torres) ;
Rodriguez-Antona, Cristina (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya)) ;
Martin, Lidia (Ipsen Pharma) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre. Servicio de Oncología Médica)
Background: Cabozantinib is approved, in various settings, for the treatment of renal cell carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been investigated for the treatment of other cancers. [...]
2022 - 10.1177/17588359221107112
Therapeutic Advances in Medical Oncology, Vol. 14 (2022)
|
|
|
3.
|
|
37 p, 420.1 KB |
Cabozantinib combination therapy for the treatment of solid tumors : a systematic review
/
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Apolo, Andrea B. (Center for Cancer Research. National Cancer Institute. National Institutes of Health) ;
Porta, Camillo (Interdisciplinary Department of Medicine. University of Bari 'Aldo Moro') ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Viteri, Santiago (Instituto Oncológico Dr. Rosell) ;
Rodriguez-Antona, Cristina (Centro Nacional de Investigaciones Oncológicas) ;
Martin, Lidia (Ipsen Pharma) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau)
Background: Cabozantinib monotherapy is approved for the treatment of several types of solid tumors. Investigation into the use of cabozantinib combined with other therapies is increasing. To understand the evidence in this area, we performed a systematic review of cabozantinib combination therapy for the treatment of solid tumors in adults. [...]
2022 - 10.1177/17588359221108691
Therapeutic Advances in Medical Oncology, Vol. 14 (2022)
|
|
|
4.
|
|
13 p, 2.9 MB |
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
/
Sierra-Rodero, Belén (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Cruz-Bermúdez, Alberto (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Nadal, Ernest (Institut d'Investigació Biomèdica de Bellvitge) ;
Garitaonaindiá, Yago (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Insa, Amelia (INCLIVA. Valencia) ;
Mosquera, Joaquín (Complejo Hospitalario Universitario de A Coruña) ;
Casal-Rubio, Joaquín (Hospital Universitario de Vigo) ;
Dómine, Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Rodríguez-Abreu, Delvys (Hospital Universitario Insular de Gran Canaria) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ;
de Castro, Javier (Hospital Universitario La Paz (Madrid)) ;
Cobo, Manuel (Hospital Regional Universitario de Málaga) ;
López Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Del Barco Morillo, Edel (Hospital Universitario de Salamanca) ;
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Barneto Aranda, Isidoro (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Viteri, Santiago (Instituto Oncológico Dr. Rosell. Hospital Universitario Quiron Dexeus) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Laza-Briviesca, Raquel (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Casarrubios, Marta (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Garciá-Grande, Aránzazu (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Romero, Atocha (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Franco, Fernando (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Provencio, Mariano (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana)
Background Pneumonitis (Pn) is one of the main immune-related adverse effects, having a special importance in lung cancer, since they share affected tissue. Despite its clinical relevance, Pn development remains an unpredictable treatment adverse effect, whose mechanisms are mainly unknown, being even more obscure when it is associated to chemoimmunotherapy. [...]
2021 - 10.1136/jitc-2021-002804
Journal for immunotherapy of cancer, Vol. 9 Núm. 8 (august 2021) , p. e002804
|
|
|
5.
|
|
14 p, 586.6 KB |
Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing : results of the RING observational trial
/
Romero, Atocha (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Jantus-Lewintre, Eloisa (Universitat Politècnica de València) ;
García-Peláez, Beatriz (Hospital Universitari Dexeus (Barcelona, Catalunya)) ;
Royuela, Ana (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Insa, Amelia (Hospital Clínic Universitari (València)) ;
Cruz Castellanos, Patricia (Hospital Universitario La Paz (Madrid)) ;
Collazo-Lorduy, Ana (Hospital Universitario HM Sanchinarro (Madrid)) ;
Pérez Altozano, Javier (Hospital Virgen de los Lirios) ;
Vidal, Oscar Juan (Hospital Universitari i Politècnic La Fe (València)) ;
Diz Taín, P (Complejo Asistencial Universitario de León) ;
Cobo, Manuel (Hospital Regional Universitario de Málaga) ;
Hernández, Berta (Complejo Hospitalario de Navarra) ;
Vázquez Estevez, Sergio (Hospital Universitario Lucus Augusti (Lugo)) ;
Benítez, Gretel (Complejo Hospitalario Universitario Insular de Gran Canaria) ;
Guirado, Maria (Hospital General Universitario de Elche) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Ortega Granados, Ana Laura (Complejo Hospitalario de Jaén) ;
Blasco, Ana (Centro de Investigación Biomédica en Red de Cáncer) ;
Bosch-Barrera, J (Institut d'Investigació Biomèdica de Girona) ;
Jurado, Jose M. (Hospital Universitario San Cecilio (Granada)) ;
García González, Jorge (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ;
Viteri, Santiago (Instituto Oncológico Dr. Rosell. Hospital Universitario Dexeus. Grupo Quiron Salud) ;
Garcia Giron, Carlos (Hospital Universitario de Burgos) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Lopez Martín, Ana (Hospital Universitario Severo Ochoa) ;
Rodriguez-Festa, Alejandro (Fundación de Investigación Biomédica del H.U. Puerta de Hierro Majadahonda) ;
Calabuig-Fariñas, Silvia (Universitat de València. Departament de Patologia) ;
Molina-Vila, Miguel Ángel (Hospital Universitari Dexeus (Barcelona, Catalunya)) ;
Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Several platforms for noninvasive EGFR testing are currently used in the clinical setting with sensitivities ranging from 30% to 100%. Prospective studies evaluating agreement and sources for discordant results remain lacking. [...]
2021 - 10.1002/1878-0261.12832
Molecular Oncology, Vol. 15 Núm. 1 (january 2021) , p. 43-56
|
|
|
6.
|
|
10 p, 654.4 KB |
Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform
/
Giménez-Capitán, Ana (Grup Quirónsalud (Barcelona, Catalunya)) ;
Bracht, Jillian (Universitat Autònoma de Barcelona) ;
García Mosquera, Juan José (Grup Quirónsalud (Barcelona, Catalunya)) ;
Jordana-Ariza, Núria (Grup Quirónsalud (Barcelona, Catalunya)) ;
García, Beatriz (Grup Quirónsalud (Barcelona, Catalunya)) ;
Garzón Ibáñez, Mónica (Grup Quirónsalud (Barcelona, Catalunya)) ;
Mayo-De-Las-Casas, Clara (Grup Quirónsalud (Barcelona, Catalunya)) ;
Viteri, Santiago (Grup Quirónsalud (Barcelona, Catalunya)) ;
Martínez-Bueno, Alejandro (Grup Quirónsalud (Barcelona, Catalunya)) ;
Aguilar-Hernández, Andrés (Grup Quirónsalud (Barcelona, Catalunya)) ;
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ;
Johnson, Eric (NanoString Technologies) ;
Huang, Chun-Ying (NanoString Technologies) ;
Gerlach, Jay L. (NanoString Technologies) ;
Warren, Sarah (NanoString Technologies) ;
Beechem, Joseph M. (NanoString Technologies) ;
Teixidó, Cristina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ;
Molina-Vila, Miguel Ángel. (Grup Quirónsalud (Barcelona, Catalunya))
BACKGROUND: With the advent of precision oncology, liquid biopsies are quickly gaining acceptance in the clinical setting. However, in some cases, the amount of DNA isolated is insufficient for Next-Generation Sequencing (NGS) analysis. [...]
2021 - 10.1093/clinchem/hvaa248
Clinical Chemistry, Vol. 67 Núm. 3 (january 2021) , p. 554-563
|
|
|
7.
|
|
13 p, 941.6 KB |
Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy
/
Casarrubios, Marta (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Cruz-Bermúdez, Alberto (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Nadal, Ernest (Institut Català d'Oncologia) ;
Insa, Amelia (Hospital Clínic Universitari (València)) ;
García Campelo, María del Rosario (Complejo Hospitalario Universitario de A Coruña) ;
Lázaro, Martín (Hospital Universitario de Vigo) ;
Dómine Gómez, Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Rodríguez-Abreu, Delvys (Hospital Universitario Insular de Gran Canaria) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ;
de Castro, Javier (Hospital Universitario La Paz (Madrid)) ;
Cobo, Manuel (Hospital Regional Universitario de Málaga) ;
López-Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Del Barco Morillo, Edel (Hospital Universitario de Salamanca) ;
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Barneto Aranda, Isidoro (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Viteri, Santiago (Instituto Oncológico Dr. Rosell. Hospital Universitario Quiron Dexeus) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Barquín, Miguel (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Laza-Briviesca, Raquel (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Sierra-Rodero, Belén (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Parra, Edwin R. (The University of Texas. Department of Translational Molecular Pathology) ;
Sanchez-Espiridion, Beatriz (The University of Texas. Department of Translational Molecular Pathology) ;
Rocha, Pedro (The University of Texas. Department of Translational Molecular Pathology) ;
Kadara, Humam (The University of Texas. Department of Translational Molecular Pathology) ;
Wistuba, Ignacio I. (The University of Texas. Department of Translational Molecular Pathology) ;
Romero, Atocha (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Calvo, Virginia (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Purpose: Characterization of the T-cell receptor (TCR) repertoire may be a promising source for predictive biomarkers of pathologic response to immunotherapy in locally advanced non-small cell lung cancer (NSCLC). [...]
2021 - 10.1158/1078-0432.CCR-21-1200
Clinical Cancer Research, Vol. 27 Núm. 21 (November 2021) , p. 5878-5890
|
|
|
8.
|
|
14 p, 2.2 MB |
Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer
/
Aguado, Cristina (Quirón Dexeus University Hospital) ;
Teixidó, Cristina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Román, Ruth (Quirón Dexeus University Hospital) ;
Reyes, Roxana (Hospital Clínic i Provincial de Barcelona) ;
Giménez-Capitán, Ana (Quirón Dexeus University Hospital) ;
Marin, Elba (Hospital Clínic i Provincial de Barcelona) ;
Cabrera, Carlos (Grup Quirónsalud (Barcelona, Catalunya)) ;
Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Castillo, Sergi (Hospital General de Granollers) ;
Muñoz, Silvia (Hospital General de Granollers) ;
Arcocha, Ainara (Hospital Clínic i Provincial de Barcelona) ;
López Vilaró, Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ;
Aldeguer, Erika (Quirón Dexeus University Hospital) ;
Rodríguez, Sonia (Quirón Dexeus University Hospital) ;
Moya, Irene (Grup Quirónsalud (Barcelona, Catalunya)) ;
Viteri, Santiago (Quiron Salud Group) ;
Cardona Zorrilla, Andrés Felipe (Clínica del Country) ;
Palmero, Ramon (L'Hospitalet) ;
Sainz, Cristina (Centro de Investigación Biomédica en Red de Cáncer) ;
Mesa-Guzmán, Miguel (Universidad Pública de Navarra) ;
Lozano, Maria D. (Universidad Pública de Navarra) ;
Aguilar-Hernández, Andrés (Grup Quirónsalud (Barcelona, Catalunya)) ;
Martínez-Bueno, Alejandro (Grup Quirónsalud (Barcelona, Catalunya)) ;
González-Cao, María (Grup Quirónsalud (Barcelona, Catalunya)) ;
Gonzalvo, Elena (Hospital Clínic i Provincial de Barcelona) ;
Leenders, William P. J. (Radboud Institute for Molecular Life Sciences) ;
Rosell, Rafael (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Montuenga, Luis M. (Universidad Pública de Navarra) ;
Prat, Aleix (Hospital Clínic i Provincial de Barcelona) ;
Molina-Vila, Miguel Ángel (Quirón Dexeus University Hospital) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona)
We studied MET alterations in 474 advanced non-small-cell lung cancer (NSCLC) patients by nCounter, an RNA-based technique. We identified 3% with MET Δex14 mRNA and 3. 5% with very-high MET mRNA expression, a surrogate of MET amplification. [...]
2020 - 10.1002/1878-0261.12861
Molecular Oncology, Vol. 15 (december 2020) , p. 350-363
|
|
|
9.
|
|
12 p, 1.4 MB |
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
/
Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Karachaliou, Niki (Instituto Oncológico Dr. Rosell, Institut Universitari Quirón-Dexeus) ;
Pilotto, Sara (Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona) ;
Codony-Servat, Jordi (Pangaea Biotech, Laboratory of Molecular Biology) ;
Cai, Xueting (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ;
Li, Xuefei (Shangai Pulmonary Hospital, Tongji University School of Medicine, Shangai) ;
Drozdowskyj, Ana (Pivotal, Madrid) ;
Codony Servat, Carles (Pangaea Biotech, Laboratory of Molecular Biology) ;
Yang, Jie (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ;
Hu, Chunping (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ;
Cardona Zorrilla, Andrés Felipe (Clinica del Country, Bogotá) ;
Lopez Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Vergnenegre, Alain (Service de Pathologie Respiratoire et d'Allergologie, CHU, Limoges France) ;
Sanchez, Jose Miguel (Hospital Universitario de la Princesa (Madrid)) ;
Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Marinis, Filippo de (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Passaro, Antonio (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Carcereny, Enric (Service de Pathologie Respiratoire et d'Allergologie, CHU, Limoges France) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ;
Garcia Campelo, Charo (Hospital Universitario de la Princesa (Madrid)) ;
Teixidó, Cristina (Pangaea Biotech, Laboratory of Molecular Biology) ;
Sperduti, Isabella (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Rodriguez, Sonia (Pangaea Biotech, Laboratory of Molecular Biology) ;
Lavazzi, Chiara (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Verlicchi, Alberto (Hospital Clínic i Provincial de Barcelona) ;
Aguirre, Itziar de (Institut Germans Trias i Pujol) ;
Queralt, C (Institut Germans Trias i Pujol) ;
Wei, Jia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Estrada-Tejedor, Roger (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ;
Puig de la Bellacasa, Raimon (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ;
Ramirez, Jose Luis (Institut Germans Trias i Pujol) ;
Jacobson, Kirstine (WV Clinical and Translational Science Institute, Morgantown, WV, USA) ;
Ditzel, Henrik J. (WV Clinical and Translational Science Institute, Morgantown, WV, USA) ;
Santarpia, Mariacarmela (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA) ;
Viteri, Santiago (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Molina, Miguel Angel (Pangaea Biotech, Laboratory of Molecular Biology) ;
Zhou, Caicun (Shangai Pulmonary Hospital, Tongji University School of Medicine, Shangai) ;
Cao, Peng (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China) ;
Ma, Patrick C. (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ;
Bivona, Trever (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Background: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non- small cell lung cancer (NSCLC) is limited by adaptive activation of cell survival signals. [...]
2017
Journal of the National Cancer Institute, Vol. 109 (september 2017) , p. 1-12
|
|
|
10.
|
|
14 p, 4.6 MB |
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases
/
De Mattos-Arruda, Leticia (Memorial Sloan Kettering Cancer Center) ;
Ng, Charlotte K. Y. (Department of Biomedicine, University of Basel, Basel, Switzerland) ;
Piscuoglio, Salvatore (University Hospital Basel (Basilea, Suïssa)) ;
Gonzalez-Cao, Maria (Grup Quirónsalud (Barcelona, Catalunya)) ;
Lim, Raymond S. (Memorial Sloan Kettering Cancer Center) ;
De Filippo, Maria R. (Memorial Sloan Kettering Cancer Center) ;
Fusco, Nicola (Memorial Sloan Kettering Cancer Center) ;
Schultheis, Anne M. (Memorial Sloan Kettering Cancer Center) ;
Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ;
Viteri, Santiago (Grup Quirónsalud (Barcelona, Catalunya)) ;
Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ;
Macedo, Gabriel S. (Memorial Sloan Kettering Cancer Center) ;
Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ;
Gómez, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Teixidó, Cristina (Grup Quirónsalud (Barcelona, Catalunya)) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Tresserra Casas, Francesc (Grup Quirónsalud (Barcelona, Catalunya)) ;
Weigelt, Britta (Memorial Sloan Kettering Cancer Center) ;
Cortés, Javier (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Seoane Suárez, Joan (Institució Catalana de Recerca i Estudis Avançats) ;
Reis-Filho, Jorge S. (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center)
Brain metastases constitute a challenge in the management of patients with HER2-positive breast cancer treated with anti-HER2 systemic therapies. Here we sought to define the repertoire of mutations private to or enriched for in HER2-positive brain metastases. [...]
2018 - 10.18632/oncotarget.25041
Oncotarget, Vol. 9 (april 2018) , p. 20617-20630
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
